Gene Mutation Clinical Trials

1 recruiting

Gene Mutation Trials at a Glance

113 actively recruiting trials for gene mutation are listed on ClinicalTrialsFinder across 6 cities in 34 countries. The largest study group is Phase 2 with 41 trials, with the heaviest enrollment activity in Boston, New York, and Houston. Lead sponsors running gene mutation studies include M.D. Anderson Cancer Center, Dana-Farber Cancer Institute, and Memorial Sloan Kettering Cancer Center.

Browse gene mutation trials by phase

Treatments under study

About Gene Mutation Clinical Trials

Looking for clinical trials for Gene Mutation? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Gene Mutation trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Gene Mutation clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 113 trials

Recruiting

TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50%

NSCLC Stage IVPD-L1 Gene MutationAtezolizumab+1 more
Antalya Training and Research Hospital150 enrolled25 locationsNCT07279402
Recruiting
Phase 2

Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment

GIST - Gastrointestinal Stromal TumorKIT Gene Mutation
Jian Li100 enrolled1 locationNCT07559864
Recruiting
Phase 2

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

Low-grade NMIBCFGFR Gene AmplificationFGFR Gene Alterations+3 more
Tyra Biosciences, Inc90 enrolled35 locationsNCT06995677
Recruiting
Phase 2

A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

Solid TumorWilms TumorRhabdoid Tumor+4 more
Memorial Sloan Kettering Cancer Center45 enrolled16 locationsNCT05985161
Recruiting

World Data on Ambroxol for Patients With GD and GBA Related PD

Gaucher DiseaseParkinson DiseaseGBA Gene Mutation
Shaare Zedek Medical Center300 enrolled3 locationsNCT04388969
Recruiting
Not Applicable

The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care

Breast CancerHead and Neck CancerGastrointestinal Cancer+2 more
University of Chicago860 enrolled1 locationNCT04541381
Recruiting

Lynch Syndrome X-Talk of Enteral Mucosa With Immune System

Hereditary Cancer SyndromeHereditary CancerLynch Syndrome+19 more
San Raffaele University300 enrolled5 locationsNCT06708429
Recruiting
Not Applicable

Videocapsule Endoscopy in Lynch Syndrome

Lynch SyndromeLynch Syndrome ILynch Syndrome II+4 more
San Raffaele University100 enrolled1 locationNCT05704010
Recruiting
Phase 3

Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders

Turner SyndromeIdiopathic Short StatureShort Stature Homeobox Gene Mutation+1 more
Ascendis Pharma A/S186 enrolled11 locationsNCT07221851
Recruiting
Phase 2

PH 2 Pemigatinib in SDH-deficient GIST

SDH Gene MutationGastrointestinal Stromal Tumor
Dana-Farber Cancer Institute24 enrolled1 locationNCT07434843
Recruiting
Phase 2

A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy

NSCLC Stage IVEGFR Gene Mutation
Tianjin Medical University Cancer Institute and Hospital25 enrolled1 locationNCT07548060
Recruiting
Phase 1Phase 2

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Non-small Cell Lung CancerMetastatic Lung CancerMetastatic Lung Non-Small Cell Carcinoma+18 more
Institut de Recherches Internationales Servier554 enrolled11 locationsNCT05786924
Recruiting
Phase 1

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

OncologyMEK MutationRAF Gene Mutation
Nested Therapeutics, Inc230 enrolled23 locationsNCT06326411
Recruiting
Phase 2

Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas

Salivary Gland CancerHER2 Gene Mutation
Dana-Farber Cancer Institute37 enrolled13 locationsNCT04620187
Recruiting
Phase 2

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

Intrahepatic CholangiocarcinomaFGFR2 Gene RearrangementFGFR2 Gene Mutation
Mehmet Akce38 enrolled2 locationsNCT06728410
Recruiting

INTERogating Cancer for Etiology, Prevention and Therapy Navigation

Malignant Solid NeoplasmCancerHematopoietic and Lymphoid System Neoplasm+2 more
Mayo Clinic500 enrolled3 locationsNCT06008392
Recruiting
Phase 1Phase 2

Alectinib Pharmacokinetic in Patients With NSCLC

ALK Gene MutationNon-small Cell Lung Cancer Stage IIIB
Instituto Nacional de Cancerologia de Mexico45 enrolled1 locationNCT05713006
Recruiting
Phase 2

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Intracranial MeningiomaRecurrent MeningiomaNF2 Gene Mutation
Alliance for Clinical Trials in Oncology124 enrolled781 locationsNCT02523014
Recruiting
Not Applicable

Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer.

Non-small Cell Lung CancerBrain MetastasesEGFR Gene Mutation
Instituto Nacional de Cancerologia de Mexico74 enrolled1 locationNCT06238882
Recruiting
Phase 1Phase 2

Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy (Myrtle)

Autosomal Dominant Optic AtrophyOPA1 Gene MutationHereditary Optic Atrophies+1 more
PYC Therapeutics18 enrolled3 locationsNCT06970106